Effects of ketoconazole on the intestinal metabolism, transport and oral bioavailability of K02, a novel vinylsulfone peptidomimetic cysteine protease inhibitor and a P450 3A, P-glycoprotein dual substrate, in male Sprague- Dawley rats

Journal of Pharmacology and Experimental Therapeutics

Volumn 287, Issue 1, 1998, Pages 246-252

  Zhang, Yuanchao ^a   Hsieh, Yunsheng ^a   Izumi, Takashi ^a   Lin, Emil T ^a   Benet, Leslie Z ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA NAPHTHOFLAVONE; CYSTEINE PROTEINASE INHIBITOR; GLYCOPROTEIN P; INDINAVIR; KETOCONAZOLE; MORPHOLINE UREA PHENYLALANINEHOMOPHENYLALANINE VINYLSULFONE PHENYL; NELFINAVIR; PROTEINASE INHIBITOR; QUINOLINE; RITONAVIR; SAQUINAVIR; SULFAPHENAZOLE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG TRANSPORT; ENZYME INHIBITION; INTESTINE SECRETION; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT;

ADMINISTRATION, ORAL; ANIMALS; ARYL HYDROCARBON HYDROXYLASES; BIOLOGICAL AVAILABILITY; BIOLOGICAL TRANSPORT; CELL LINE; CYSTEINE PROTEINASE INHIBITORS; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; DIPEPTIDES; INTESTINES; KETOCONAZOLE; MALE; OXIDOREDUCTASES, N-DEMETHYLATING; P-GLYCOPROTEIN; RATS; RATS, SPRAGUE-DAWLEY; SULFONES;

EID: 0032467550     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Benet LZ, Kroetz DL and Sheiner LB (1996) Pharmacokinetics: The dynamics of drug absorption, distribution, and elimination, in Goodman & Gilman's The Pharmacological Basis of Therapeutics (Hardman JH, Limbird LE, Molinoff PB, Ruddon RW and Gilman AG eds) pp 3-28, McGraw-Hill, New York.
2. Bornheim LM and Correia MA (1989) Effect of cannabidiol on cytochrome P-450 isozymes. Biochem Pharmacol 38:2789-2794.
3. Chiba M, Hensleigh M and Lin JH (1997) Hepatic and intestinal metabolism of indinavir, an HIV protease inhibitor, in rat and human microsomes. Major role of CYP3A. Biochem Pharmacol 53:1187-1195.
4. Fitzsimmons ME and Collins JM (1997) Selective biotransformation of the human immunodeficiency virus protease inhibitor saquinavir by human small-intestinal cytochrome P4503A4: potential contribution to high first-pass metabolism. Drug Metab Dispos 25:256-266.
5. Floren LC, Bekersky I, Benet LZ, Mekki Q, Dressler D, Lee JW, Roberts JP and Hebert MF (1997) Tacrolimus oral bioavailability doubles with coadministration of ketoconazole. Clin Pharmacol Ther 62:41-49.
6. Gomez DY, Wacher VJ, Tomlanovich SJ, Hebert MF and Benet LZ (1996) The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine. Clin Pharmacol Ther 58:15-19.
7. Gottesman MM and Pastan I (1993) Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 62:385-427.
8. Halpert JR, Guengerich FP, Bend JR and Correia MA (1994) Selective inhibitors of cytochromes P450. Toxicol Appl Pharmacol 125:163-175.
9. Hebert MF, Roberts JP, Prueksaritanont T and Benet LZ (1992) Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. Clin Pharmacol Ther 52:453-457.
10. Hunter J, Jepson MA, Tsuruo T, Simmons N and Hirst BH (1993) Functional expression of P-glycoprotein in apical membranes of human intestinal Caco-2 cells. J Biol Chem 268:14991-14997.
11. Kolars JC, Lown KS, Schmiedlin-Ren P, Ghosh M, Fang C, Wrighton SA, Merion RM and Watkins PB (1994) CYP3A gene expression in human gut epithelium. Pharmacogenetics 4:247-259.
12. Kolars JC, Schmiedlin-Ren P, Dobbins WO 3rd, Schuetz J, Wrighton SA and Watkins PB (1992a) Heterogeneity of cytochrome P450IIIA expression in rat gut epithelia. Gastroenterology 102:1186-1198.
13. Kolars JC, Schmiedlin-Ren P, Schuetz JD, Fang C and Watkins PB (1992b) Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. J Clin Invest 90:1871-1878.
14. Kumar GN, Rodrigues AD, Buko AM and Denissen JF (1996) Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. J Pharmacol Exp Ther 277:423-431.
15. Li AP, Kaminski DL and Rasmussen A (1995) Substrates of human hepatic cytochrome P450 3A4. Toxicology 104:1-8.
16. Lin JH, Chiba M, Balani SK, Chen I, Kwei GY, Vastag KJ and Nishime JA (1996) Species differences in the pharmacokinetics and metabolism of indinavir, a potent human immunodeficiency virus protease inhibitor. Drug Metab Dispos 24:1111-1120.
17. McGrath ME, Eakin AE, Engel JC, McKerrow JH, Craik CS and Fletterick RJ (1995) The crystal structure of Cruzain: A therapeutic target for Chagas' disease. J Mol Biol 247:251-259.
18. McKerrow JH, McGrath ME and Engel JC (1995) The cysteine protease of Trypanosoma cruzi as a model for antiparasite drug design. Parasitol Today 11:279-282.
19. McKinnon RA, Burgess WM, Hall PM, Roberts-Thomson SJ, Gonzalez FJ and McManus ME (1995) Characterisation of CYP3A gene subfamily expression in human gastrointestinal tissues. Gut 36:259-267.
20. Omura T and Sato R (1964) The carbon monoxide-binding pigment of liver microsomes II. Solubilization, purification, and properties. J Biol Chem 239:2370-2378.
21. Palmer JT, Rasnick D, Klaus JL and Bromme D (1995) Vinylsulfones as mechanism-based cysteine protease inhibitors. J Med Chem 38:3193-3196.
22. Pastan I, Gottesman MM, Ueda K, Lovelace E, Rutherford AV and Willingham MC (1988) A retrovirus carrying an MDR1 cDNA confers multidrug resistance and polarized expression of P-glycoprotein in MDCK cells. Proc Natl Acad Sci USA 85:4486-4490.
23. Perry CM and Benfield P (1997) Nelfinavir. Drugs 54:81-7; discussion 88.
24. Schinkel AH, Wagenaar E, van Deemter L, Mol CA and Borst P (1995) Absence of the mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J Clin Invest 96:1698-1705.
25. Shimada T, Yamazaki H, Mimura M, Inui Y and Guengerich FP (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 caucasians. J Pharmacol Exp Ther 270:414-423.
26. Siegsmund MJ, Cardarelli C, Aksentijevich I, Sugimoto Y, Pastan I and Gottesman MM (1994) Ketoconazole effectively reverses multidrug resistance in highly resistant KB cells. J Urol 151:485-491.
27. Sparreboom A, van Asperen J, Mayer U, Schinkel AH, Smit JW, Meijer DK, Borst P, Nootien WJ, Beijnen JH and van Tellingen O (1997) Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci USA 94:2031-2035.
28. Spina E, Avenoso A, Campo GM, Scordo MG, Caputi AP and Perucca E (1997) Effect of ketoconazole on the pharmacokinetics of imipramine and desipramine in healthy subjects. Br J Clin Pharmacol 43:315-318.
29. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I and Willingham MC (1987) Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 84:7735-7738.
30. Thummel KE, O'Shea D, Paine MF, Shen DD, Kunze KL, Perkins JD and Wilkinson GR (1996) Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin Pharmacol Ther 59:491-502.
31. Wacher VJ, Wu CY and Benet LZ (1995) Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog 13:129-134.
32. Watkins PB, Wrighton SA, Schuetz EG and Guzelian PS (1987) Identification of glucocorticoid-inducible cytochrome P-450 in the intestine mucosa of rats and human. J Clin Invest 80:1029-1036.
33. Yuan JH, Stolzenbach JC, Salamon CM, Snook SS and Schoenhard GL (1997) Improvement of bioavailability of the HIV protease inhibitor SC-52151 in the beagle dog by coadministration of the CYP3A4 inhibitor, ketoconazole. Xenobiotica 27:489-497.
34. Zhang Y, Guo X, Lin ET and Benet LZ (1998) Overlapping substrate specificity of cytochrome P450 3A and P-glycoprotein for a novel cysteine protease inhibitor. Drug Metab Dispos 26:360-366.